tirzepatide safety vs semaglutide safety as Compared with for the Treatment of Obesity Tirzepatide vs Semaglutide: A Comprehensive

It does not significantly affect appetite, body weight, or the incretin system

48-week clinical data: ~21% body weight reduction #1: Retatrutide The first triple-agonist, activating GLP-1, GIP, and glucagon receptors

Tsukiyama K, Yamada Y, Yamada C, et al

They were the primary supply source during the shortage era

Telehealth Providers offering FDA-Approved Medications Stick With FDA-Approved GLP-1s With the FDA officially banning compounded semaglutide and tirzepatide, the safest and most legal path forward is to stick with name-brand GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro

Medications such as Wegovy or Zepbound should not be used in people with a personal or family history of medullary thyroid cancer